Pharmacological management of low milk supply with domperidone: Separating fact from fiction

Medical Journal of Australia

Volumn 201, Issue 5, 2014, Pages 257-258

  Grzeskowiak, Luke E ^a   Amir, Lisa H ^b,c  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b LA TROBE UNIVERSITY   (Australia)

^c ROYAL WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DOMPERIDONE; DOPAMINE 2 RECEPTOR; METOCLOPRAMIDE; PROLACTIN; DOPAMINE RECEPTOR BLOCKING AGENT;

BREAST FEEDING; BREAST MILK; BREAST SURGERY; CESAREAN SECTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; FAMILY HISTORY; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART DEATH; HUMAN; LACTATION; MATERNAL DISEASE; MATERNAL SMOKING; MILK PRODUCTION; MORBIDITY; MORTALITY; MOTHER CHILD RELATION; NOTE; QT PROLONGATION; AGE; CHEMICALLY INDUCED; DEATH, SUDDEN, CARDIAC; INFANT; LACTATION DISORDERS; MALE; METHODOLOGY; OFF LABEL DRUG USE; SEX DIFFERENCE;

AGE FACTORS; ARRHYTHMIAS, CARDIAC; BREAST FEEDING; DEATH, SUDDEN, CARDIAC; DOMPERIDONE; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; INFANT; LACTATION DISORDERS; MALE; OFF-LABEL USE; RESEARCH DESIGN; SEX FACTORS;

EID: 84907327302     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja14.00626     Document Type: Note

References (10)

1. Stuebe AM, Schwarz E.B. The risks and benefits of infant feeding practices for women and their children. J Perinatol 2010; 30: 155-162.
2. Odom EC, Li R, Scanlon KS, et al. Reasons for earlier than desired cessation of breastfeeding. Pediatrics 2013; 131: e726-e732.
3. Amir L.H. Breastfeeding: managing 'supply' difficulties. Aust Fam Physician 2006; 35: 686-689.
4. Zuppa AA, Sindico P, Orchi C, et al. Safety and efficacy of galactogogues: substances that induce, maintain and increase breast milk production. J Pharm Pharm Sci 2010; 13: 162-174.
5. Osadchy A, Moretti ME, Koren G. Effect of domperidone on insufficient lactation in puerperal women: a systematic review and meta-analysis of randomized controlled trials. Obstet Gynecol Int 2012; 2012: 642893.
6. European Medicines Agency. PRAC recommends restricting use of domperidone. London, UK: EMA, 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Domperidone_31/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee/WC500162559.pdf (accessed Apr 2014).
7. Johannes CB, Varas-Lorenzo C, McQuay LJ, et al. Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacoepidemiol Drug Saf 2010; 19: 881-888
8. van Noord C, Dieleman JP, van Herpen G, et al. Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands. Drug Saf 2010; 33: 1003-1014.
9. Grzeskowiak LE, Lim SW, Thomas AE, et al. Audit of domperidone use as a galactogogue at an Australian tertiary teaching hospital. J Hum Lact 2013; 29: 32-37.
10. Deasy C, Bray JE, Smith K, et al. Out-of-hospital cardiac arrests in young adults in Melbourne, Australia. Resuscitation 2011; 82: 830-834